JP6484612B2 - 改善された治療リガンドの取得 - Google Patents

改善された治療リガンドの取得 Download PDF

Info

Publication number
JP6484612B2
JP6484612B2 JP2016518523A JP2016518523A JP6484612B2 JP 6484612 B2 JP6484612 B2 JP 6484612B2 JP 2016518523 A JP2016518523 A JP 2016518523A JP 2016518523 A JP2016518523 A JP 2016518523A JP 6484612 B2 JP6484612 B2 JP 6484612B2
Authority
JP
Japan
Prior art keywords
atom
iota
theta
atoms
ligand
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2016518523A
Other languages
English (en)
Japanese (ja)
Other versions
JP2016527481A (ja
JP2016527481A5 (https=
Inventor
シ、ジエ
シーウォード ベイカー、テレンス
シーウォード ベイカー、テレンス
デイヴィッド グリフィス ローソン、アラステア
デイヴィッド グリフィス ローソン、アラステア
リュー、シャオフェン
Original Assignee
ユーシービー バイオファルマ エスピーアールエル
ユーシービー バイオファルマ エスピーアールエル
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ユーシービー バイオファルマ エスピーアールエル, ユーシービー バイオファルマ エスピーアールエル filed Critical ユーシービー バイオファルマ エスピーアールエル
Publication of JP2016527481A publication Critical patent/JP2016527481A/ja
Publication of JP2016527481A5 publication Critical patent/JP2016527481A5/ja
Application granted granted Critical
Publication of JP6484612B2 publication Critical patent/JP6484612B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B5/00—ICT specially adapted for modelling or simulations in systems biology, e.g. gene-regulatory networks, protein interaction networks or metabolic networks
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B15/00—ICT specially adapted for analysing two-dimensional [2D] or three-dimensional [3D] molecular structures, e.g. structural or functional relations or structure alignment
    • G16B15/30—Drug targeting using structural data; Docking or binding prediction
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16C—COMPUTATIONAL CHEMISTRY; CHEMOINFORMATICS; COMPUTATIONAL MATERIALS SCIENCE
    • G16C20/00—Chemoinformatics, i.e. ICT specially adapted for the handling of physicochemical or structural data of chemical particles, elements, compounds or mixtures
    • G16C20/50—Molecular design, e.g. of drugs
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16C—COMPUTATIONAL CHEMISTRY; CHEMOINFORMATICS; COMPUTATIONAL MATERIALS SCIENCE
    • G16C20/00—Chemoinformatics, i.e. ICT specially adapted for the handling of physicochemical or structural data of chemical particles, elements, compounds or mixtures
    • G16C20/90—Programming languages; Computing architectures; Database systems; Data warehousing
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B15/00—ICT specially adapted for analysing two-dimensional [2D] or three-dimensional [3D] molecular structures, e.g. structural or functional relations or structure alignment
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A90/00—Technologies having an indirect contribution to adaptation to climate change
    • Y02A90/10—Information and communication technologies [ICT] supporting adaptation to climate change, e.g. for weather forecasting or climate simulation

Landscapes

  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Theoretical Computer Science (AREA)
  • Spectroscopy & Molecular Physics (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Biophysics (AREA)
  • Medicinal Chemistry (AREA)
  • Computing Systems (AREA)
  • Evolutionary Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medical Informatics (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Physiology (AREA)
  • Organic Chemistry (AREA)
  • Databases & Information Systems (AREA)
  • Software Systems (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Information Retrieval, Db Structures And Fs Structures Therefor (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Steroid Compounds (AREA)
JP2016518523A 2013-06-13 2014-06-13 改善された治療リガンドの取得 Active JP6484612B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB1310544.0 2013-06-13
GBGB1310544.0A GB201310544D0 (en) 2013-06-13 2013-06-13 Obtaining an improved therapeutic ligand
PCT/EP2014/062478 WO2014198951A2 (en) 2013-06-13 2014-06-13 Obtaining an improved therapeutic ligand

Publications (3)

Publication Number Publication Date
JP2016527481A JP2016527481A (ja) 2016-09-08
JP2016527481A5 JP2016527481A5 (https=) 2017-07-20
JP6484612B2 true JP6484612B2 (ja) 2019-03-13

Family

ID=48914497

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2016518523A Active JP6484612B2 (ja) 2013-06-13 2014-06-13 改善された治療リガンドの取得

Country Status (15)

Country Link
US (2) US20160125124A1 (https=)
EP (1) EP3008648B1 (https=)
JP (1) JP6484612B2 (https=)
KR (1) KR20160019504A (https=)
CN (1) CN105308602B (https=)
AU (1) AU2014280055A1 (https=)
BR (1) BR112015031171A2 (https=)
CA (1) CA2914726A1 (https=)
CL (1) CL2015003591A1 (https=)
GB (1) GB201310544D0 (https=)
HK (1) HK1218579A1 (https=)
MX (1) MX2015016822A (https=)
RU (1) RU2016100234A (https=)
SG (2) SG11201510084TA (https=)
WO (1) WO2014198951A2 (https=)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL296732A (en) 2020-03-27 2022-11-01 UCB Biopharma SRL Autonomous knob domain peptides
CN113380320B (zh) * 2021-07-01 2022-03-15 中国海洋大学 基于阳性化合物残基贡献相似度的分子对接结果筛选方法
CN115708166A (zh) * 2021-08-20 2023-02-21 北京望石智慧科技有限公司 一种药物分子设计方法、装置、电子设备及存储介质
CN114530215B (zh) * 2022-02-18 2023-03-28 北京有竹居网络技术有限公司 设计配体分子的方法和装置
CN115171774A (zh) * 2022-05-17 2022-10-11 慧壹科技(上海)有限公司 一种抗体/大分子药物的亲和力改造系统和方法
CN121712809A (zh) 2023-07-03 2026-03-20 Ucb生物制药有限责任公司 工程化的aav衣壳蛋白
GB202314896D0 (en) 2023-09-28 2023-11-15 UCB Biopharma SRL Knob domain proteins

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5331573A (en) * 1990-12-14 1994-07-19 Balaji Vitukudi N Method of design of compounds that mimic conformational features of selected peptides
US5642292A (en) 1992-03-27 1997-06-24 Akiko Itai Methods for searching stable docking models of biopolymer-ligand molecule complex
GB0011818D0 (en) * 2000-05-16 2000-07-05 Inpharmatica Ltd Lead molecule generation
US20020025535A1 (en) 2000-06-15 2002-02-28 Diller David J. Prioritization of combinatorial library screening
AU2001279973A1 (en) 2000-08-21 2002-03-04 Ribotargets Limited Computer-based modelling of ligand/receptor structures
JP2004511803A (ja) * 2000-10-16 2004-04-15 オーソ−マクニール・フアーマシユーチカル・インコーポレーテツド バニロイド受容体についての改良リガンド結合アッセイ
AU2002246737B2 (en) * 2000-12-29 2007-03-01 Savient Pharmaceuticals, Inc. Specific human antibodies for selective cancer therapy
US20030148391A1 (en) * 2002-01-24 2003-08-07 Salafsky Joshua S. Method using a nonlinear optical technique for detection of interactions involving a conformational change
EP1620548A2 (en) 2003-05-07 2006-02-01 Duke University Protein design for receptor-ligand recognition and binding
US20060105390A1 (en) * 2003-10-29 2006-05-18 Yi Zhang Method of characterizing heterogeneity in receptor-ligand interactions and related method of assay signal histogram transformation
JP2005181104A (ja) * 2003-12-19 2005-07-07 Hitachi Ltd 高精度ドッキングスコアリング方法
JP4719223B2 (ja) 2005-03-11 2011-07-06 シュレディンガー エルエルシー 結合親和性を推定するための予測的スコア関数
GB0620729D0 (en) 2006-10-18 2006-11-29 Ucb Sa Biological products
US20090006040A1 (en) 2007-05-24 2009-01-01 Peter Hrnciar Systems and Methods for Representing Protein Binding Sites and Identifying Molecules with Biological Activity
EP2216429A4 (en) 2007-11-12 2011-06-15 In Silico Sciences Inc SILICO SCREENING SYSTEM AND SILICO SCREENING METHOD
GB0807413D0 (en) 2008-04-23 2008-05-28 Ucb Pharma Sa Biological products
JPWO2010110288A1 (ja) * 2009-03-24 2012-09-27 株式会社カネカ 免疫グロブリンに親和性を有するタンパク質および免疫グロブリン結合性アフィニティーリガンド
US9023876B2 (en) * 2010-07-08 2015-05-05 Adhaere Pharmaceuticals, Inc. Compounds and methods for regulating integrins
ME02734B (me) 2011-01-14 2017-10-20 Ucb Biopharma Sprl Antitelo koje vezuje il-17a i il-17f

Also Published As

Publication number Publication date
JP2016527481A (ja) 2016-09-08
CN105308602A (zh) 2016-02-03
CL2015003591A1 (es) 2016-08-05
EP3008648B1 (en) 2023-05-10
US20160125124A1 (en) 2016-05-05
RU2016100234A (ru) 2018-02-06
BR112015031171A2 (pt) 2017-07-25
GB201310544D0 (en) 2013-07-31
RU2016100234A3 (https=) 2018-03-23
SG11201510084TA (en) 2016-01-28
CA2914726A1 (en) 2014-12-18
US20210005277A1 (en) 2021-01-07
EP3008648A2 (en) 2016-04-20
SG10201707917UA (en) 2017-10-30
MX2015016822A (es) 2016-04-13
WO2014198951A3 (en) 2015-08-27
CN105308602B (zh) 2019-09-27
AU2014280055A1 (en) 2016-01-28
HK1218579A1 (zh) 2017-02-24
US11942188B2 (en) 2024-03-26
WO2014198951A2 (en) 2014-12-18
KR20160019504A (ko) 2016-02-19

Similar Documents

Publication Publication Date Title
JP6484612B2 (ja) 改善された治療リガンドの取得
Wlodawer et al. Detect, correct, retract: How to manage incorrect structural models
Lewis et al. Current methods for site-directed structure generation
Sivasubramanian et al. Structural model of the mAb 806-EGFR complex using computational docking followed by computational and experimental mutagenesis
JP2002536301A (ja) タンパク質モデリングツール
US20140100834A1 (en) Computational methods for analysis and molecular design of antibodies, antibody humanization, and epitope mapping coupled to a user-interactive web browser with embedded three- dimensional rendering
Liang et al. De novo protein design by an energy function based on series expansion in distance and orientation dependence
CN118918981A (zh) 基于人源抗体骨架库生成抗体的方法、装置和设备及存储介质
JP4314128B2 (ja) タンパク質立体構造と誘導適合を利用したリガンド探索方法
JP2012524124A (ja) 回転異性体ライブラリーおよびその使用方法
Leis et al. ReFlexIn: a flexible receptor protein-ligand docking scheme evaluated on HIV-1 protease
Gu et al. A multilayer dynamic perturbation analysis method for predicting ligand–protein interactions
Madan et al. Principles and aspects of molecular docking: A bird’s eye view
Mishra et al. In silico engineering of proteins that recognize small molecules
Peng et al. Atom-level generative foundation model for molecular interaction with pockets
JP2006252485A (ja) リガンド探索装置、リガンド探索方法、プログラム、および記録媒体
WO2005103994A1 (ja) リガンド分子の形状作成方法および装置
CN113874395A (zh) 鉴定表位和互补位的方法
Kasana et al. Design and Development of Machine Learning Model for Antibody Design: Rituximab a Case Study.
Rios Zertuche et al. Nanodesigner: resolving the complex-CDR interdependency with iterative refinement
Wong et al. Unveiling Interaction Signatures Across Viral Pathogens through VASCO: Viral Antigen-Antibody Structural COmplex dataset
Lee et al. Mutation-induced reshaping of protein conformational dynamics revealed by a coarse-grained modeling framework
Collins Dockground Protein Docking Benchmark Sets and Assessment Resource
Zhao et al. Agent-guided de novo design of nanobody binders against a novel cancer target
Sampson et al. A functional investigation of antibody Fc-FcRn variant binding guided by* in silico* free energy perturbation methods

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20170609

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20170609

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20180327

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20180404

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20190109

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190124

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20190212

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20190218

R150 Certificate of patent or registration of utility model

Ref document number: 6484612

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250